Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP) will present late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail AP-SA02 at IDWeek 2025 in Atlanta, GA.

The oral presentation, titled "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia," will be given by Dr. Loren G. Miller on Wednesday, October 22, 2025, from 10:30 AM to 11:45 AM ET in room B401-B402 during the session "Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections."

LOS ANGELES, Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025^™, which is being held October 19-22, 2025, in Atlanta, GA.

Details of the oral presentation are as follows:

Presentation Title:	A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia
Presenter:	Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute
Session:	Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections
Location:	B401-B402
Date:	Wednesday, October 22, 2025
Time:	10:30 AM - 11:45 AM ET

About IDWeek 2025^™
IDWeek 2025^™ is a joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). With the theme "Advancing Science, Improving Care," IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2025^™ takes place October 19-22 in Atlanta, GA. For more information, visit www.idweek.org.

About AP-SA02 and diSArm Study
Armata is developing AP-SA02, a fixed multi-phage phage cocktail, for the treatment of complicated bacteremia caused by Staphylococcus aureus (S. aureus), including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains.

The diSArm study (NCT05184764) is a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (BAT) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. The results from the diSArm study are an important step forward in Armata's effort to confirm the potent antimicrobial activity of phage therapy and the completion of the study represents a significant milestone in the development of AP-SA02, moving Armata one step closer to introducing an effective new treatment option to patients suffering from complicated S. aureus bacteremia. diSArm represents the first clear evidence in a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity and mortality in the United States.

The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.

About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 21, 2025, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. 

Media Contacts:

At Armata:

Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025-302582563.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When will Armata (ARMP) present Phase 2a AP-SA02 data at IDWeek 2025?

Armata will present on Wednesday, October 22, 2025 from 10:30 AM to 11:45 AM ET in room B401-B402.

What clinical trial will Armata (ARMP) discuss for AP-SA02 at IDWeek 2025?

A Phase 2a randomized, double-blind, controlled IV trial of AP-SA02 versus placebo alongside best available antibiotic therapy in complicated Staphylococcus aureus bacteremia.

Who is presenting Armata's (ARMP) late-breaking AP-SA02 data at IDWeek 2025?

Dr. Loren G. Miller, M.D., M.P.H., professor of medicine at David Geffen School of Medicine at UCLA and chief of infectious diseases at Harbor-UCLA, is the presenter.

Which session will feature Armata's (ARMP) AP-SA02 presentation at IDWeek 2025?

The presentation is in the session titled "Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections."

What should investors expect from Armata's (ARMP) IDWeek 2025 presentation?

Investors should expect a late-breaking Phase 2a clinical data presentation on AP-SA02 assessing efficacy and safety in complicated Staphylococcus aureus bacteremia.

Where and how long is Armata's (ARMP) AP-SA02 oral presentation at IDWeek 2025?

The oral presentation is in Atlanta, GA, room B401-B402, scheduled for 75 minutes on October 22, 2025 from 10:30 AM to 11:45 AM ET.